Amgen (AMGN) Capital Expenditures (2009 - 2026)

For the trailing twelve months through Jun 30, 2026, Capital Expenditures at Amgen was $2.3 billion, up 63.6% year-over-year; for FY2025, it came in at $1.86 billion, up 69.5% from FY2024.

• Annual Capital Expenditures shows a five-year compound annual growth rate of 25.0% (FY2020 to FY2025).
• In prior years, Amgen's Capital Expenditures was $1.1 billion in FY2024 (-1.4%), $1.11 billion in FY2023 (+18.8%), $936 million in FY2022 (+6.4%) and $880 million in FY2021 (+44.7%).
• Quarterly Capital Expenditures has run from a low of $160 million in Q3 2022 to a high of $712 million in Q1 2026 over five years.
• On a year-over-year basis, Capital Expenditures has increased in each of the last eight quarters, with growth averaging 55.2% over the last eight quarters.
• The strongest year-over-year quarter for Capital Expenditures in the past five years was Q1 2023, with growth of 81.1%; the weakest was Q3 2022, with a decline of 33.9%.
• According to Business Quant data, Capital Expenditures for the three prior quarters was $712 million (Q1 2026), $642 million (Q4 2025) and $436 million (Q3 2025).